KOSEN 한인과학기술자네트워크

Lung Diseases Primary Sponsor: Department of Health and Human Services Deadline: 4/1/2001; 8/1/2001; 12/1/2001 KEYWORDS Lung Diseases The NHLBI Division of Lung Diseases (DLD) maintains surveillance over developments in pulmonary research and assesses the Nation's need for research on the causes, prevention, diagnosis, and treatment of pulmonary diseases. Also within the purview of the Division are: technology development, application of research findings, and research training and career development in pulmonary diseases. The DLD plans and directs the research and training programs which encompass basic research, applied research and development, clinical investigations, clinical trials, and demonstration and education research. Two programs comprise the Division of Lung Diseases: the Airway Biology and Disease Program, and the Lung Biology and Disease Program. 1. Airway Biology and Disease Program. Focuses on basic and clinical research, education and training related to chronic obstructive pulmonary diseases, asthma, cystic fibrosis, control of breathing, bronchiolitis, respiratory neurobiology, sleep, and other adult airway diseases. 2. Lung Biology and Disease Program. Supports research, education, and training programs in lung cell and vascular biology; lung growth and development and pediatric lung disease; acute lung injury and critical care medicine; interstitial lung diseases, including pulmonary fibrosis; and AIDS and tuberculosis. A. Diagnostic Tools 1. Computer algorithms for reading and comparing chest radiographs and scans (computed tomography, radioisotopes, etc.) using digitized images. 2. Diagnose and treat respiratory abnormalities during sleep in infants, children, and adults. 3. Imaging techniques to monitor lung cell functions in vivo. 4. Noninvasive measurement of blood gases, hemodynamics and respiratory function in infants, in children, and in adults. 5. Noninvasive methodologies for measuring airways inflammation in asthma. 6. Noninvasive methods to detect pulmonary thromboembolism, hypertension, and edema. 7. Probes to monitor peripheral tissue oxygenation in vivo. 8. Use of ambulatory monitoring techniques to diagnose and manage respiratory disorders of sleep. 9. Use of high-resolution computerized tomography for monitoring lung function. 10. X-ray computerized tomography to quantify pulmonary disease processes. B. Information and Health Education Tools 1. Computer technologies to promote adoption and implementation of asthma clinical practice guidelines in medical practice. 2. Health education methodologies for patients, families, or communities to prevent or cope with lung diseases or to reduce their impact, especially among people with asthma who are minorities or living in poverty. 3. Improve smoking cessation programs. 4. Information systems to coordinate patient management and monitoring among patients and health care professionals. 5. Interventions to reduce passive smoking in infants and children. 6. Use of interactive and computer technology to teach self management to asthma and chronic obstructive lung disease patients. C. Materials and Devices 1. Blood substitutes to improve gas exchange. 2. Emergency, portable, and servo-controlled ventilatory support devices. 3. Improved aerosol delivery systems. 4. Improved devices for continuous oxygen administration, including airline travel. 5. Improved extracorporeal or implantable devices for blood gas exchange (artificial lung). 6. New approaches and technologies that can be used to engineer functional tissue, in vitro, for replacement or repair of damaged or diseased lung tissue, in vivo. 7. Personal exposure monitors for aeroallergens and other environmental pollutants. 8. Thrombo-resistant materials for extracorporeal or implantable devices for blood gas exchange and for indwelling catheters. D. Methods 1. "Clean" animal models for Pneumocystis carinii infections. 2. Culture Pneumocystis carinii in vitro. 3. Determine viability and enumeration of infectious Pneumocystis carinii organisms. 4. Development and standardization of in vitro systems for the study of pulmonary epithelial (airway) cells and pulmonary endothelial (vascular) cells. 5. Identification of genes causing and modifying lung diseases. 6. Identify and detect lung cell specific differentiation markers. 7. Identify lung stem cell types. 8. Identify species and strain differences of Pneumocystis carinii. 9. Isolate, identify, and characterize cells found in pulmonary granulomas. 10. Methods to monitor levels of alertness or sleepiness continuously over extended periods of time. 11. Three-dimensional static, mathematical, cell culture models of airways and alveoli to define parameters determining aeropollutant absorption, deposition, and effects. E. Treatments 1. Delivery of specific drugs (e.g., antioxidants, artificial proteinase inhibitors, surfactant) to the lungs for treatment of pulmonary and non-pulmonary diseases. 2. Gene therapy for cystic fibrosis, alpha1antitrypsin deficiency, primary pulmonary hypertension, and other inborn errors of metabolism affecting the lungs. 3. Improved aerosol delivery systems. 4. Novel pharmacologic and gene therapy approaches for asthma, acute lung injury, idiopathic pulmonary fibrosis, and bronchopulmonary dysplasia. 5. Novel pharmacologic approaches for treatment of sleep apnea. 6. Pharmacological means of stimulating growth and repair of alveoli and reparative or restorative elastogenesis in lungs suffering emphysematous changes. For additional information on research topics, contact: Heart and Vascular Diseases Dr. Rosalie Dunn Division of Heart and Vascular Diseases 6701 Rockledge Drive, Room 9196 (301) 435-0505; Fax: (310) 480-1454 Email: rd39w@nih.gov Lung Diseases Dr. Robert Musson Division of Lung Diseases 6701 Rockledge Drive, Room 10108 Bethesda, MD 20892-7952 (301) 435-0222; Fax: (301) 480-3557 Email: rm65o@nih.gov Ms. Ann Rothgeb Division of Lung Diseases 6701 Rockledge Drive, Room 10114 Bethesda, MD 20892-7952 (301) 435-0202; Fax: (301) 480-3557 Email: ar31t@nih.gov Blood Diseases and Resources Ms. Susan E. Pucie Division of Blood Diseases and Blood Resources 6701 Rockledge Drive, Room 10166 Bethesda, MD 20892-7950 (301) 435-0079; Fax: (301) 480-0867 Email: sp34j@nih.gov Epidemiology and Clinical Applications Dr. Thomas Blaszkowski Division of Epidemiology and Clinical Applications 6701 Rockledge Drive, Room 8106 Bethesda, MD 20892-7938 (301) 496-1841; Fax: (301) 496-0075 Email: tb33i@nih.gov For administrative and business management questions, contact: Mr. Ed Donohue National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 7160 Bethesda, MD 20892-7926 (301) 435-0144; Fax: (301) 480-3310 Email: ed25b@nih.gov NOTE: The Solicitations listed on this site are partial copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should always use the suggested links on our reference pages. These will take you directly to the appropriate agency information where you can read the official version of the solicitation you are interested in. The official link for this page is: http://grants.nih.gov/grants/funding/sbir.htm. Solicitation closing dates are: April 1, August 1, and December 1, 2001.